GlaxoSmithKline is not looking to offload its consumer business. Bloomberg reports that the UK drugmaker refuted a Financial Times article that indicated a spin-off was imminent.

This does not mean it could not happen—GSK  tells Bloomberg it won’t turn the consumer business into a free-standing operation “in the near term.”